Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)

Journal of Hepatology

Volumn 61, Issue 5, 2014, Pages 994-1003

  Poynard, Thierry ^a,b,c   Vergniol, Julien ^d   Ngo, Yen ^e   Foucher, Juliette ^d   Thibault, Vincent ^a   Munteanu, Mona ^e   Merrouche, Wassil ^d   Lebray, Pascal ^a   Rudler, Marika ^a   Deckmyn, Olivier ^e   Perazzo, Hugo ^a   Thabut, Dominique ^a   Ratziu, Vlad ^a   De Ledinghen, Victor ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e Biopredictive   (France)

Author keywords

Chronic hepatitis B; Cirrhosis complications; Elastography; Fibrosis stages; FibroSure; FibroTest ; Hepatocellular carcinoma; Prognostic factors; Progression of fibrosis in virological responders; Regression fibrosis; Surrogate markers

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CHRONIC HEPATITIS B; DISEASE COURSE; DISEASE SEVERITY ASSESSMENT; DYNAMICS; ELASTOGRAPH; ELASTOGRAPHY; ESOPHAGUS VARICES; FEMALE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; TREATMENT RESPONSE; VALIDATION STUDY; VIRUS LOAD; BLOOD; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; COHORT ANALYSIS; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; HEPATITIS B, CHRONIC; HETEROZYGOTE; LIVER NEOPLASMS; PROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; COHORT STUDIES; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84932111887     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.06.027     Document Type: Article

References (31)

1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 2008;48: 335-352.
2. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007;47: 598-607.
3. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010;51: 1445-1449.
4. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39: 222-230.
5. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 2006;55: 403-408.
6. Castera L. Hepatitis B: Are non-invasive markers of liver fibrosis reliable? Liver Int 2014;34: 91-96.
7. Salkic NN, Jovanovic P, Hauser G, Brcic M. Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: A meta-Analysis. Am J Gastroenterol 2014;109: 796-809.
8. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr Hepat Rep 2011;10: 87-97.
9. Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: A metaanalysis. PLoS One 2012;7: E44930.
10. Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (Fibro-Test®-ActiTest) and viral load. PLoS One 2008;3: E2573.
11. Poynard T, Ngo Y, Munteanu M, et al. Biomarkers of liver injury for hepatitis clinical trials: A meta-Analysis of longitudinal studies. Antivir Ther 2010;15: 617-631.
12. Castéra L, Bernard PH, Le Bail B, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther 2011;33: 455-465.
13. Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fibrosis biomarker (FibroTest®) for assessing liver fibrosis progression: Proof of concept and first application in a large population. J Hepatol 2012;57: 541-548.
14. Poynard T, Ngo Y, Perazzo H, et al. Prognostic value of liver fibrosis biomarkers: A meta-Analysis. Gastroenterol Hepatol (N Y) 2011;7: 445-454.
15. de Lédinghen V, Vergniol J, Barthe C, et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther 2013;37: 979-988.
16. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013;57: 399-408.
17. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest®) and transient elastography (FibroScan®). J Hepatol 2013;60: 706-714.
18. Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013;59: 675-683.
19. Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver injury biomarker FibroTest®. A reappraisal at 7 years of age. BMC Gastroenterol 2011;11: 39.
20. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13, 369 examinations. Hepatology 2010;51: 828-835.
21. Yapali S, Talaat N, Lok AS. Management of hepatitis B: Our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 2014;12: 16-26.
22. Chao T, Lim JK, Ayoub WS, Nguyen LH, Nguyen MH. Systematic review with meta-Analysis: The proportion of chronic hepatitis B patients with normal alanine transaminase guidet640 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther 2014;39: 349-358.
23. Poynard T, Lenaour G, Vaillant JC, et al. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol 2012;10: E7.
24. Hintze J. NCSS 8. Kaysville, Utah, USA: NCSS, LLC; 2012, www.ncss.com.
25. Chon YE, Jung ES, Park JY, et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol 2012;46: 518-525.
26. Kim BK, Kim SU, Kim HS, et al. Prospective validation of FibroTest® in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One 2012;7: E35825.
27. Shi KQ, Fan YC, Pan ZZ, et al. Transient elastography: A meta-Analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013;33: 62-71.
28. Wang JH, Chuah SK, Lu SN, et al. Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus-related cirrhosis. J Gastroenterol Hepatol 2012;27: 1213-1218.
29. Wong GL, Chan HL, Chan HY, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144: 933-944.
30. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year openlabel follow-up study. Lancet 2013;381: 468-475.
31. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-Term lamivudine therapy. Gastroenterology 2003;124: 105-117.